Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082310 | 0.82 | CDC25B (0.51) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL27782308 | 0.82 | NAPRT (0.48) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL31253326 | 0.81 | CYP1A2 (0.46) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL7537222 | 0.81 | CYP1A2 (0.46) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL7523649 | 0.79 | KDM4E (0.50) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL1520617 | 0.79 | ALDH1A1 (0.47) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL564729 | 0.79 | KDM4E (0.41) | ALDH1A1TSHRKDM4EHPGDMAPT | |
| SCHEMBL29621628 | 0.79 | ALDH1A1 (0.47) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL5355792 | 0.77 | GABRP (0.62) | CYP1A2SELLSELPALDH1A1CA12 | |
| SCHEMBL7536407 | 0.77 | GABRP (0.42) | CYP1A2SELLSELPALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS INC. | 2024-09-03 | — | — | US | claimed |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-31 | — | — | US | claimed |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | KEMPHARM, INC. (US) | 2022-02-01 | — | — | US | claimed |
| US-20200390757-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2020-12-17 | — | — | US | claimed |
| WO-2018191474-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | KEMPHARM, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2017-11-02 | — | — | US | claimed |
| EP-3226907-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS AND MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3223819-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE | Kempharm, Inc. (US) | 2017-10-04 | — | — | EP | claimed |
| US-20160168160-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2016-06-16 | — | — | US | claimed |
| WO-2016089951-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS AND MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2016-06-09 | — | — | WO | claimed |
| US-20160151352-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2016-06-02 | — | — | US | claimed |
| WO-2016086113-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE | KEMPHARM, INC. (US) | 2016-06-02 | — | — | WO | claimed |
| WO-2011119637-A9 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS | STEMINA BIOMARKER DISCOVERY, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| EP-2771002-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2013063204-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM, INC. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | claimed |
| EP-2550365-A1 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS | Stemina Biomarker Discovery, Inc. (US) | 2013-01-30 | — | — | EP | claimed |
| WO-2011119637-A1 | PREDICTING HUMAN DEVELOPMENTAL TOXICITY OF PHARMACEUTICALS USING HUMAN STEM-LIKE CELLS AND METABOLOMICS | STEMINA BIOMARKER DISCOVERY, INC. (US) | 2011-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390757-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | CYP1A2 240/4885SELL 2268/4885SELP 1791/4885 |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 31/4885SELL 906/4885SELP 2089/4885 |
| US-20160151352-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 31/4885SELL 906/4885SELP 2089/4885 |
| US-12076316-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | CYP1A2 240/4885SELL 2268/4885SELP 1791/4885 |
| US-20160168160-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | CYP1A2 36/4885SELL 1432/4885SELP 3126/4885 |
| US-11234975-B2 | Levorphanol prodrugs and processes for making and using them | OPRM1, OPRL1, OPRK1 | CYP1A2 240/4885SELL 2268/4885SELP 1791/4885 |
| US-20130150395-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, CYP2D6 | CYP1A2 27/4885SELL 1604/4885SELP 2362/4885 |
| US-20220096463-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OPRK1 | CYP1A2 240/4885SELL 2268/4885SELP 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.